Work

The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear

Year: 2014

Type: article

Source: Thrombosis Research

DOI: 10.1016/j.thromres.2014.11.009

Authors: Cassandra P. Loren, Joseph E. Aslan, Rachel A. Rigg, Marie S. Nowak, Laura D. Healy, András Gruber, Brian J. Druker, Owen J.T. McCarty

Institutions: Université de Lille, Boston University, Howard Hughes Medical Institute, Oregon Health & Science University, OHSU Knight Cancer Institute

Language: English

Topic: Platelet Disorders and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Foundation for the National Institutes of Health, American Heart Association, National Institutes of Health, Oregon Clinical and Translational Research Institute, National Heart, Lung, and Blood Institute, National Cancer Institute, National Center for Research Resources, National Center for Advancing Translational Sciences

Awards: Oregon Clinical and Translational Research Institute, G2148971391, G3256272670, G3806589214, Oregon Clinical and Translational Research Institute, G8419720682, Characterization of Coagulation Factor-platelet Interactions: Role of FXI, OHSU Knight Cancer Institute

OpenAlex ID: W2072625253

FWCI: 3.31

Cites: 36

Cited by: 79

Related to: 10